Lipella Pharmaceuticals Inc. Files 8-K on Shareholder Vote

TL;DR

Lipella Pharma had a shareholder vote on Sept 10th, details to follow.

AI Summary

Lipella Pharmaceuticals Inc. filed an 8-K on September 11, 2024, reporting on matters submitted to a vote of security holders on September 10, 2024. The filing does not disclose the specific outcomes of the vote or the proposals presented.

Why It Matters

This filing indicates a shareholder vote occurred, which could signal significant corporate decisions or changes being made by Lipella Pharmaceuticals Inc.

Risk Assessment

Risk Level: medium — The filing is an 8-K reporting a shareholder vote, which can precede significant corporate actions, but lacks specific details on the vote's outcome or proposals.

Key Numbers

• 005-93847 — Commission File Number (Identifier for the company's filings)
• 20-2388040 — IRS Employer Identification No. (Tax identification number)

Key Players & Entities

• Lipella Pharmaceuticals Inc. (company) — Registrant
• September 11, 2024 (date) — Filing Date
• September 10, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Pittsburgh, PA (location) — Principal executive office

FAQ

Key Financial Figures

• $0.0001 — registered Common Stock, par value $0.0001 per share LIPO The Nasdaq Stock Mar

Filing Documents

• g084428_8k.htm (8-K) — 43KB
• 0001753926-24-001565.txt ( ) — 215KB
• lipo-20240911.xsd (EX-101.SCH) — 3KB
• lipo-20240911_lab.xml (EX-101.LAB) — 33KB
• lipo-20240911_pre.xml (EX-101.PRE) — 22KB
• g084428_8k_htm.xml (XML) — 4KB

07

Item 5.07 Submission of Matters to a Vote of Security Holders. On September 10, 2024, Lipella Pharmaceuticals Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). Set forth below are the three proposals that were voted on at the Annual Meeting and the stockholder votes on each such proposal, as certified by the inspector of elections for the Annual Meeting. These proposals are described in further detail in the Definitive Proxy Statement filed by the Company with the U.S. Securities and Exchange Commission on August 12, 2024 (the "Proxy Statement"). As of the close of business on August 1, 2024, the record date for the Annual Meeting, 8,004,636 shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), were issued, outstanding and entitled to vote. Holders of shares of Common Stock were entitled to one vote per share for each share of Common Stock held by them. Stockholders holding an aggregate of 4,303,168 votes were present at the Annual Meeting, virtually or represented by proxy, which number constituted a quorum. Proposal 1 – The seven (7) director nominees named in the Proxy Statement were elected by a plurality of the votes cast by holders of the shares present and entitled to vote at the Annual Meeting to serve as the Company's directors until the Company's 2025 Annual Meeting of Stockholders and until each of their respective successors are elected and qualified or until each of their earlier resignation or removal. The final voting results with respect to the election of each such nominee were as follows: Nominee For Withheld Jonathan Kaufman 2,565,343 34,547 Michael Chancellor 2,560,987 38,903 Lori Birder 2,561,241 38,649 Daniel Cohen 2,535,335 64,555 Byong (Christopher) Kim 2,529,909 69,981 Ryan Pruchnic 2,535,877 64,013 Naoki Yoshimura 2,569,463 30,427 There were 1,703,278 broker non-votes with respect to each such nominee for the first

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 11, 2024 Lipella Pharmaceuticals Inc. By: /s/ Jonathan Kaufman Name: Jonathan Kaufman Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR